AstraZeneca and Merck report Lynparza’s significant survival benefits in high-risk breast cancer and Keytruda combo results in ovarian cancer.
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
